Toggle navigation
Campus Access
About MPG.eBooks
Skip to content
Search Tips
Home
>
Search: "Costs"
Language
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文(繁體)
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
All Fields
Title
Person
Topic
ISBN/ISSN
Year
Collection
Advanced
Retain my current filters
author_facet:"CADTH Canadian Drug Expert Committee"
language:"English"
Showing
1
-
20
of
125
Search:
'"Costs"'
,
query time: 0.01s
Book List
0
Sort:
Relevance
Year Descending
Year Ascending
Author
Title
Read Now
1
CADTH Canadian Drug Expert Committee recommendation: Nitisinone (Orfadin -- Sobi Canada Inc.) : indication: the treatment of adult and pediatric patients with hereditary tyrosinemi...
Published 2018
CADTH
Subjects:
“
...Drug
Costs
...
”
Read Now
2
CADTH Canadian Drug Expert Committee final recommendation: Mifepristone and misoprostol (Mifegymiso -- Celopharma Inc.) : indication: medical termination of pregnancy
Published 2017
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...
Cost
-Benefit Analysis...
”
Read Now
3
CADTH Canadian Drug Expert Committee final recommendation: Mifepristone and misoprostol (Mifegymiso -- Celopharma Inc.) : indication: medical termination of pregnancy
Published 2017
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...
Cost
-Benefit Analysis...
”
Read Now
4
CADTH Canadian Drug Expert Committee final recommendation: Sarilumab (Kevzara -- Sanofi Genzyme) : indication: rheumatoid arthritis
Published 2017
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...
Cost
-Benefit Analysis...
”
Read Now
5
CADTH Canadian Drug Expert Committee final recommendation: Canagliflozin and metformin hydrochloride (Invokamet -- Janssen Inc.) : type 2 diabetes mellitus
Published 2016
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Drug
Costs
...
”
Read Now
6
CADTH Canadian Drug Expert Committee final recommendation: Sarilumab (Kevzara -- Sanofi Genzyme) : indication: rheumatoid arthritis
Published 2017
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...
Cost
-Benefit Analysis...
”
Read Now
7
CADTH Canadian Drug Expert Committee final recommendation: Omalizumab -- resubmission (Xolair -- Novartis Pharmaceuticals Canada Inc.) : indication: asthma
Published 2016
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...
Cost
-Benefit Analysis...
”
Read Now
8
CADTH Canadian Drug Expert Committee final recommendation: Omalizumab -- resubmission (Xolair -- Novartis Pharmaceuticals Canada Inc.) : indication: asthma
Published 2016
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...
Cost
-Benefit Analysis...
”
Read Now
9
CADTH Canadian Drug Expert Committee recommendation: Ivabradine hydrochloride (Lancora -- Servier Canada Inc.) : indication: heart failure, NYHA class II to III.
Published 2017
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...
Cost
-Benefit Analysis...
”
Read Now
10
CADTH Canadian Drug Expert Committee recommendation: Tocilizumab (Actemra - Hoffmann-La Roche Limited) : indication : giant cell arteritis
Published 2018
CADTH
Subjects:
“
...Drug
Costs
...
”
Read Now
11
CADTH Canadian Drug Expert Committee recommendation: Ivabradine hydrochloride (Lancora -- Servier Canada Inc.) : indication: heart failure, NYHA class II to III.
Published 2017
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...
Cost
-Benefit Analysis...
”
Read Now
12
CADTH Canadian Drug Expert Committee final recommendation: Ixekizumab (Taltz -- Eli Lilly Canada Inc.) : indication: moderate to severe plaque psoriasis
Published 2016
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...
Cost
-Benefit Analysis...
”
Read Now
13
CADTH Canadian Drug Expert Committee recommendation: Nitisinone (MDK-Nitisinone -- mendeliKABs inc.) : indication : the treatment of adult and pediatric patients with hereditary ty...
Published 2018
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...
Cost
-Benefit Analysis...
”
Read Now
14
CADTH Canadian Drug Expert Committee final recommendation: Dapagliflozin (Forxiga -- AstraZeneca Canada Inc.) indication : type 2 diabetes
Published 2016
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Drug
Costs
...
”
Read Now
15
CADTH Canadian Drug Expert Committee final recommendation: Ixekizumab (Taltz -- Eli Lilly Canada Inc.) : indication: moderate to severe plaque psoriasis
Published 2016
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...
Cost
-Benefit Analysis...
”
Read Now
16
CADTH Canadian drug expert committee recommendation: Latanoprost (Monoprost -- Laboratoires Thea) : indication : glaucoma and ocular hypertension
Published 2018
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...
Cost
-Benefit Analysis...
”
Read Now
17
CADTH Canadian Drug Expert Committee recommendation: Apomorphine hydrochloride (Movapo -- Paladin Labs Inc.) : indication : Parkinson's disease
Published 2018
CADTH
Subjects:
“
...Drug
Costs
...
”
Read Now
18
CADTH Canadian Drug Expert Committee final recommendation: Emtricitabine / tenofovir alafenamide (Descovy -- Gilead Sciences Canada, Inc.) indication : HIV-1 infection
Published 2016
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Drug
Costs
...
”
Read Now
19
CADTH Canadian drug expert committee recommendation: Latanoprost (Monoprost -- Laboratoires Thea) : indication : glaucoma and ocular hypertension
Published 2018
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...
Cost
-Benefit Analysis...
”
Read Now
20
CADTH Canadian Drug Expert Committee recommendation: AbobotulinumtoxinA (Dysport therapeutic -- Ipsen Biopharmaceuticals Canada Inc.) : indication: for the symptomatic treatment of...
Published 2017
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...
Cost
-Benefit Analysis...
”
1
2
3
4
5
6
7
Back
Narrow Search
Remove Filters
Clear Filter
Author: CADTH Canadian Drug Expert Committee
Clear Filter
Language: English
Year of Publication
From:
To:
Classification
610 - Medicine & health
120
330 - Economics
89
140 - Specific philosophical schools
12
700 - The arts; fine & decorative arts
9
580 - Plants (Botany)
1
800 - Literature & rhetoric
1
Language
English
Collection
National Center for Biotechnology Information
125
Author
CADTH Canadian Drug Expert Committee
Canadian Agency for Drugs and Technologies in Health
91
Search Tools
Get RSS Feed
Share Search
https://ebooks.mpdl.mpg.de/ebooks/Search/Results?filter%5B%5D=author_facet%3A%22CADTH+Canadian+Drug+Expert+Committee%22&filter%5B%5D=language%3A%22English%22&lookfor=%22Costs%22&type=Subject
Send by Email
×
Loading...